TNFSF11 and hypercalcemia disease: For bone metastatic patients, bisphosphonates and denosumab, a human monoclonal antibody against receptor activator of nuclear factor κ-B ligand (RANKL) could inhibit bone resorption and improve bone density to relieve pain and tumor-induced hypercalcemia [18,19].